Sorafenib: targeting multiple tyrosine kinases in cancer.
about
Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase InhibitorsAnti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcomaTransgenic plants as low-cost platform for chemotherapeutic drugs screeningIn vitro and in vivo antiangiogenic activity of desacetylvinblastine monohydrazide through inhibition of VEGFR2 and Axl pathwaysArtemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs.Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings.Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis.High fms-like tyrosine kinase-3 (FLT3) receptor surface expression predicts poor outcome in FLT3 internal tandem duplication (ITD) negative patients in adult acute myeloid leukaemia: A prospective pilot study from India.The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review).Hepatic arterial administration of sorafenib and iodized oil effectively attenuates tumor growth and intrahepatic metastasis in rabbit VX2 hepatocellular carcinoma model.Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells.The coffee diterpene kahweol enhances sensitivity to sorafenib in human renal carcinoma Caki cells through down-regulation of Mcl-1 and c-FLIP expression.
P2860
Q26851417-D4AD5B37-A13A-4743-9ADA-DABE1E6FB550Q34354781-942BBC21-BE6D-4AFB-9857-15A568635677Q35016736-F44BC96E-A11E-4AB3-91D8-A430413D3E76Q36879511-52366A25-E184-4641-81B4-BFB2240012EAQ36916456-43AE48FF-8B28-4882-ADA8-3A11CF83CD01Q38557907-E70F35A4-52B4-4979-8245-F63E589662D5Q38974167-697B6D5E-8C59-4BBE-8584-030699542D9BQ39283692-039AC973-60EA-4DBD-AD4F-4DB2756E903AQ39401616-AEC24987-2C4F-4675-87BB-51C6AEEC5B1FQ41637262-E5A0782D-6F3A-48A3-965A-DD076CB7B658Q43147742-8634F433-D1B3-4C3D-BDAF-5BAEFBFEA32AQ46215513-C5D872AC-10DB-48D2-AE11-42EC55D64190
P2860
Sorafenib: targeting multiple tyrosine kinases in cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Sorafenib: targeting multiple tyrosine kinases in cancer.
@ast
Sorafenib: targeting multiple tyrosine kinases in cancer.
@en
Sorafenib: targeting multiple tyrosine kinases in cancer.
@nl
type
label
Sorafenib: targeting multiple tyrosine kinases in cancer.
@ast
Sorafenib: targeting multiple tyrosine kinases in cancer.
@en
Sorafenib: targeting multiple tyrosine kinases in cancer.
@nl
prefLabel
Sorafenib: targeting multiple tyrosine kinases in cancer.
@ast
Sorafenib: targeting multiple tyrosine kinases in cancer.
@en
Sorafenib: targeting multiple tyrosine kinases in cancer.
@nl
P1476
Sorafenib: targeting multiple tyrosine kinases in cancer.
@en
P2093
Jens Hasskarl
P304
P356
10.1007/978-3-642-54490-3_8
P577
2014-01-01T00:00:00Z